Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-15

Clinical Trial Update: BAX 326 Surgery Study in Hemophilia B Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for BAX 326 (FVIII) in Hemophilia B has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAX 326 (recombinant factor IX)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2017-02-15